Creutzfeldt-Jakob disease (CJD) is a rare and degenerative brain disorder that falls under the category of prion diseases of which our firm offers a full range of vaccine and therapeutic development services for the researchers and scientists working within this sphere.
Overview of Creutzfeldt-Jakob Disease (CJD)
The condition exhibits the rapid onset of dementia as well as difficulties with coordination and other neurological issues. It is estimated that one or two cases of sCJD prion disease occur every million people resulting in it being the common form of sCJD. However, if you have evaluated a larger population, STX6 and GAL3ST1 are sCJD-causing genetic prions, that in addition to the mutation of the prion gene, have been identified. These discoveries add a new perspective to the current theories regarding CJD and its genetic components.
Fig.1 Variants of CJD and symptoms. (Rasheed, U., et al., 2024)
Pathogenesis of Creutzfeldt-Jakob Disease (CJD)
When one speaks of CJD, the first characteristic feature that suggests itself is that of the prion protein that is misfolded which would normal prion proteins to misfold. This cascade of misfolding events thus set into motion a harmful chain of events culminating in prion deposition along with spongiform changes of the nerve tissue, neuronal deprivation, and proliferation of Astrocytes. These proteins also form aggregates within the cell and inhibit normal functioning of the brain thereby contributing to the various features of CJD.
Fig.2 Trafficking of PrPSc and PrPC through endocytic and secretory pathways and relationship with SNARE protein STX6. (Jones, E., and Mead, S., 2020)
Vaccine Development for Creutzfeldt-Jakob Disease (CJD)
There is much pessimism as to the development of an effective vaccine against CJD. However, in the past few years, there has been some scintilla of progress in some of the:
This vaccine aims to target prion-like proteins by administering an attenuated strain of the CJD agent.
To inject a little piece of DNA that contains the code for a specific protein to stimulate the immune system.
To employ the prion protein peptides and oligodeoxynucleotide-CpG to create an immune activity in animals.
Therapeutics Development for Creutzfeldt-Jakob Disease (CJD)
|
Types |
Names |
Mechanism of Action |
Targets |
Research Phase |
| Aminopyridine compounds |
Flupirtine |
A pyridine derivative with analgesic and anti-apoptotic properties |
Potassium channel |
Clinical trials |
| Anticoagulant |
Pentosan polysulphate |
Reduce PrPSc formation |
/ |
Clinical trials |
| Antiprotozoal drug |
Quinacrine |
Target the conversion of PrPC into PrPSc |
Aldehyde oxidase |
Clinical trials |
| Antibiotic |
Doxycycline |
Binding PrPSc conformers, hindering their assembly into amyloid fibrils |
30S subunit |
Phase II trials |
| Anti-PrPC antibody |
PRN100 |
Prion protein inhibitors |
PRNP |
Clinical trials |
Our Services
We help researchers by providing them with sophisticated laboratory tools, infectious disease models, modern vaccines, and therapeutic innovation services. Additionally, we support cutting-edge CJD research by supplying high-quality resources and advanced research equipment.
Featured Services of Creutzfeldt-Jakob Disease (CJD)
- CJD-A21 model
- TgMHu2ME199K model
- ki-3F4-CJD model
- Tg23 model
- Tg5182 model
- Tg14210 model
- Others
Why Choose Us
Owing to our steadfast commitment toward the performance of our duties, innovative projects, and satisfactory compliance of our clients we become one of the best partners for researchers and scientists. Through integration services, the intention is to enhance the effectiveness of research and make strides in understanding and combating CJD disease and others.
If you are interested in our services, we invite you to reach out to us for further information and to obtain detailed quotations tailored to your research requirements.
References
- Jones, Emma, and Simon Mead. "Genetic risk factors for Creutzfeldt-Jakob disease." Neurobiology of disease 142 (2020): 104973.
- Rasheed, Urwah et al. "A systemic analysis of Creutzfeldt Jakob disease cases in Asia." Prion 18.1 (2024): 11-27.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
